Ionotropic glutamate receptors

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

Retrieved on: 
Tuesday, July 20, 2021
Branches of biology, Psychoactive drugs, Neurochemistry, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, Neurotransmitters, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.

Key Points: 
  • Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.
  • Arbormentis LLC is a privately-held drug discovery company engaged in potentially transformative innovations for CNS diseases.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Glutamate, Biology, NMDA receptor antagonists, Molecular neuroscience, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid

An archived replay of the event will be available for one year after the conclusion of the presentation.

Key Points: 
  • An archived replay of the event will be available for one year after the conclusion of the presentation.
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Drugs, NMDA receptor antagonists, Psychoactive drugs, Glutamate, Ionotropic glutamate receptors, Cell signaling, NMDA receptor, N-Methyl-D-aspartic acid, Forward-looking statement, Ketamine, Channel blocker

Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.

Key Points: 
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021

Retrieved on: 
Saturday, May 1, 2021
Branches of biology, Drugs, Psychoactive drugs, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, General anesthetics, Nicotinic antagonists, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid, Antidepressant

In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.

Key Points: 
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Drugs, Psychoactive drugs, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, General anesthetics, Nicotinic antagonists, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid, Antidepressant

In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.

Key Points: 
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Psychoactive drugs, Drugs, NMDA receptor antagonists, Glutamate, Molecular neuroscience, Antidepressants, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

The webcast will be available for 90 days after the presentation.\nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).

Key Points: 
  • The webcast will be available for 90 days after the presentation.\nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Aptinyx to Participate in Upcoming Conferences

Retrieved on: 
Tuesday, April 27, 2021
Mental health, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Neuroscience, Neural circuits, Glutamate, Neurophysiology, Neuroplasticity, Ionotropic glutamate receptors, NMDA receptor, Nervous system, Synaptic plasticity

ET on April 29, 2021; and\n7th Annual Truist Securities Life Sciences Summit \xe2\x80\x93 Aptinyx management will participate in one-on-one meetings with investors throughout the conference on May 4 \xe2\x80\x93 5, 2021.\nAptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

Key Points: 
  • ET on April 29, 2021; and\n7th Annual Truist Securities Life Sciences Summit \xe2\x80\x93 Aptinyx management will participate in one-on-one meetings with investors throughout the conference on May 4 \xe2\x80\x93 5, 2021.\nAptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate\xe2\x80\x94rather than block or over-activate\xe2\x80\x94NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment.
  • Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021

Retrieved on: 
Friday, March 26, 2021
Branches of biology, Biology, Glutamate, Ionotropic glutamate receptors, Anticonvulsants, Nitriles, Perampanel, Pyridines, AMPA receptor, Eisai, Glutamate receptor, Receptor antagonist

TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.

Key Points: 
  • TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.
  • The reasons for the selection of this discovery research for the award are outlined by the PSJ as follows.
  • Although glutamate receptors, which are responsible for neuronal excitation, have long been recognized as important drug discovery targets, they have not led to the creation of any drugs.
  • It has been demonstrated that perampanel is a selective, non-competitive AMPA receptor antagonist.

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021

Retrieved on: 
Thursday, March 18, 2021
Branches of biology, Drugs, Neurochemistry, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, Molecular neuroscience, NMDA receptor, Ketamine, N-Methyl-D-aspartic acid

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).

Key Points: 
  • Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

MIJ 821: Developed by Novartis for Treatment Resistant Depression - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
Pharmaceutical, Health, Clinical trials, Branches of biology, Ionotropic glutamate receptors, Life sciences, Biology, NMDA receptor antagonists, GRIN2B, Major depressive disorder, Novartis, NMDA receptor, Mij, Treatment-resistant depression

MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.

Key Points: 
  • MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.
  • "MIJ 821 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Other emerging products for Treatment Resistant Depression are giving market competition to MIJ 821 and launch of late-stage emerging therapies in the near future will significantly impact the market.